Pfizer said on July 30 that it has filed for a label expansion for its congenital hemophilia therapy Hympavzi (marstacimab) to include children aged six to under 12 years. The company also filed for the approval of a new 75…
To read the full story
Related Article
- Pfizer Files Hympavzi for Hemophilia with Inhibitors
December 11, 2025
- Pfizer Rolls Out Hemophilia Therapy Hympavzi in Japan
March 25, 2025
BUSINESS
- Arthur D. Little Urges Pricing Revamp to Spur Regenerative Medicine in Japan
October 21, 2026
- Entyvio PIV Trial Links Disease Clearance to 70% Lower UC Complication Risk
October 21, 2026
- Toho Subsidiary Suffers Data Breach, HCP Info Exposed
October 20, 2026
- Veritas, Toray Pin Down Hit Compounds for PCSK9 mRNA Drugs
October 20, 2026
- Insmed’s Brinsupri Hits Japan Market for NCFB
October 20, 2026
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…





